Charles River Laboratories Execs Purchase Shares in Confidence of Company's Future

Details

James C. Foster, and Corporate Executive Vice President and COO, Ms. Birgit Girshick, each purchased shares of the company's common stock, reflecting their confidence in the company's strategic direction and long-term growth prospects. The purchases were made in open market transactions totaling approximately $1 million and $250,000, respectively. Additionally, both executives terminated their Rule 10b5-1 Trading Plans to avoid potential conflicts with short swing profit rules.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.